(GH) Guardant Health - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40131M1099

Blood Tests, Tissue Tests, Liquid Biopsy, Companion Diagnostics, Data Platform

Health Care Services
Market Cap in USD: 14,123m
IPO / Inception: 2018-10-04
12m vs SPY: 139%

EPS (Earnings per Share)

EPS (Earnings per Share) of GH over the last years for every Quarter: "2020-12": -0.94, "2021-03": -1.09, "2021-06": -0.96, "2021-09": -1.06, "2021-12": -0.89, "2022-03": -1.21, "2022-06": -1.27, "2022-09": -1.41, "2022-12": -1.36, "2023-03": -1.3, "2023-06": -0.67, "2023-09": -0.73, "2023-12": -0.85, "2024-03": -0.94, "2024-06": -0.84, "2024-09": -0.88, "2024-12": -0.62, "2025-03": -0.49, "2025-06": -0.44, "2025-09": -0.39, "2025-12": 0,
EPS CAGR: 55.64%
EPS Trend: 88.8%
Last SUE: 3.35
Qual. Beats: 4

Revenue

Revenue of GH over the last years for every Quarter: 2020-12: 78.316, 2021-03: 78.665, 2021-06: 92.101, 2021-09: 94.779, 2021-12: 108.108, 2022-03: 96.099, 2022-06: 109.144, 2022-09: 117.404, 2022-12: 126.891, 2023-03: 128.714, 2023-06: 137.15, 2023-09: 143.03, 2023-12: 155.054, 2024-03: 168.491, 2024-06: 177.235, 2024-09: 191.476, 2024-12: 201.814, 2025-03: 203.471, 2025-06: 232.088, 2025-09: 265.196, 2025-12: null,
Rev. CAGR: 27.03%
Rev. Trend: 98.9%
Last SUE: 3.39
Qual. Beats: 6

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 61.3%
Value at Risk 5%th 87.5%
Relative Tail Risk -13.25%
Reward TTM
Sharpe Ratio 1.93
Alpha 184.61
CAGR/Max DD 0.91
Character TTM
Hurst Exponent 0.648
Beta 1.056
Beta Downside 1.181
Drawdowns 3y
Max DD 59.79%
Mean DD 21.34%
Median DD 18.44%

Description: GH Guardant Health January 08, 2026

Guardant Health, Inc. (NASDAQ:GH) is a precision-oncology firm that commercializes a suite of liquid-biopsy and tissue-based genomic tests-including Guardant360, Guardant360 CDx, GuardantINFINITY, and GuardantConnect-to identify actionable mutations and support clinical trial enrollment for cancer patients worldwide.

Key recent metrics: FY 2023 revenue reached approximately $1.1 billion, up ~30 % YoY, driven largely by Guardant360 CDx adoption; the company reported a cash runway of roughly 18 months after a $300 million financing round in Q3 2024; and its partnership with Roche to co-develop companion diagnostics for KRAS-mutated colorectal cancer is expected to expand market penetration.

Sector dynamics that materially affect Guardant: the global liquid-biopsy market is projected to grow at a CAGR of 23 % through 2030, buoyed by increasing payer reimbursement for non-invasive testing and a shift toward earlier-stage cancer detection; meanwhile, regulatory trends-such as the FDA’s recent guidance on next-generation sequencing companion diagnostics-create both compliance costs and entry barriers that favor incumbents with cleared assays.

For a deeper, data-driven assessment of Guardant’s valuation relative to these trends, you may find the ValueRay analysis worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-398.8m TTM) > 0 and > 6% of Revenue (6% = 54.2m TTM)
FCFTA -0.21 (>2.0%) and ΔFCFTA -2.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 65.59% (prev 148.7%; Δ -83.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.17 (>3.0%) and CFO -222.9m > Net Income -398.8m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (125.3m) change vs 12m ago 1.83% (target <= -2.0% for YES)
Gross Margin 63.76% (prev 81.07%; Δ -17.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 64.11% (prev 44.99%; Δ 19.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -117.3 (EBITDA TTM -354.1m / Interest Expense TTM 3.36m) >= 6 (WARN >= 3)

Altman Z'' -8.01

(A) 0.46 = (Total Current Assets 828.9m - Total Current Liabilities 236.9m) / Total Assets 1.28b
(B) -2.24 = Retained Earnings (Balance) -2.87b / Total Assets 1.28b
warn (B) unusual magnitude: -2.24 — check mapping/units
(C) -0.28 = EBIT TTM -394.2m / Avg Total Assets 1.41b
(D) -1.76 = Book Value of Equity -2.87b / Total Liabilities 1.63b
Total Rating: -8.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.98

1. Piotroski 1.50pt
2. FCF Yield -1.76%
3. FCF Margin -29.05%
4. Debt/Equity -3.74
5. Debt/Ebitda -2.11
6. ROIC - WACC (= -54.90)%
7. RoE 151.9%
8. Rev. Trend 98.90%
9. EPS Trend 88.82%

What is the price of GH shares?

As of January 13, 2026, the stock is trading at USD 110.17 with a total of 2,412,031 shares traded.
Over the past week, the price has changed by +8.15%, over one month by +8.67%, over three months by +78.47% and over the past year by +189.16%.

Is GH a buy, sell or hold?

Guardant Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy GH.
  • Strong Buy: 15
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the GH price?

Issuer Target Up/Down from current
Wallstreet Target Price 118.2 7.3%
Analysts Target Price 118.2 7.3%
ValueRay Target Price 111.4 1.1%

GH Fundamental Data Overview January 10, 2026

P/S = 15.6471
P/B = 55.6696
Beta = 1.591
Revenue TTM = 902.6m USD
EBIT TTM = -394.2m USD
EBITDA TTM = -354.1m USD
Long Term Debt = 1.11b USD (from longTermDebt, last quarter)
Short Term Debt = 26.4m USD (from shortTermDebt, last quarter)
Debt = 1.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 746.4m USD (from netDebt column, last quarter)
Enterprise Value = 14.87b USD (14.12b + Debt 1.33b - CCE 580.0m)
Interest Coverage Ratio = -117.3 (Ebit TTM -394.2m / Interest Expense TTM 3.36m)
EV/FCF = -56.70x (Enterprise Value 14.87b / FCF TTM -262.2m)
FCF Yield = -1.76% (FCF TTM -262.2m / Enterprise Value 14.87b)
FCF Margin = -29.05% (FCF TTM -262.2m / Revenue TTM 902.6m)
Net Margin = -44.18% (Net Income TTM -398.8m / Revenue TTM 902.6m)
Gross Margin = 63.76% ((Revenue TTM 902.6m - Cost of Revenue TTM 327.1m) / Revenue TTM)
Gross Margin QoQ = 64.71% (prev 65.01%)
Tobins Q-Ratio = 11.65 (Enterprise Value 14.87b / Total Assets 1.28b)
Interest Expense / Debt = 0.07% (Interest Expense 943.0k / Debt 1.33b)
Taxrate = -0.15% (negative due to tax credits) (136.0k / -92.6m)
NOPAT = -394.8m (EBIT -394.2m * (1 - -0.15%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.50 (Total Current Assets 828.9m / Total Current Liabilities 236.9m)
Debt / Equity = -3.74 (negative equity) (Debt 1.33b / totalStockholderEquity, last quarter -354.5m)
Debt / EBITDA = -2.11 (negative EBITDA) (Net Debt 746.4m / EBITDA -354.1m)
Debt / FCF = -2.85 (negative FCF - burning cash) (Net Debt 746.4m / FCF TTM -262.2m)
Total Stockholder Equity = -262.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.33% (Net Income -398.8m / Total Assets 1.28b)
RoE = 151.9% (negative equity) (Net Income TTM -398.8m / Total Stockholder Equity -262.6m)
RoCE = -46.27% (EBIT -394.2m / Capital Employed (Equity -262.6m + L.T.Debt 1.11b))
RoIC = -45.93% (negative operating profit) (NOPAT -394.8m / Invested Capital 859.7m)
WACC = 8.97% (E(14.12b)/V(15.45b) * Re(9.81%) + D(1.33b)/V(15.45b) * Rd(0.07%) * (1-Tc(-0.00)))
Discount Rate = 9.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.83%
Fair Price DCF = unknown (Cash Flow -262.2m)
EPS Correlation: 88.82 | EPS CAGR: 55.64% | SUE: 3.35 | # QB: 4
Revenue Correlation: 98.90 | Revenue CAGR: 27.03% | SUE: 3.39 | # QB: 6
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.004 | Revisions Net=+1 | Analysts=12
EPS next Year (2026-12-31): EPS=-1.44 | Chg30d=-0.004 | Revisions Net=+0 | Growth EPS=+20.4% | Growth Revenue=+27.2%

Additional Sources for GH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle